D3R/MOR antagonist 1

HY-149386	
C ₂₂ H ₂₇ Cl ₂ N ₃ O	
420.38	
Dopamine Receptor; Opioid Receptor	
GPCR/G Protein; Neuronal Signaling	
Please store the product under the recommended conditions in the Certificate of Analysis.	\langle
	C ₂₂ H ₂₇ Cl ₂ N ₃ O 420.38 Dopamine Receptor; Opioid Receptor GPCR/G Protein; Neuronal Signaling Please store the product under the recommended conditions in the Certificate of

BIOLOGICAL ACTIV	
Description	D3R/MOR antagonist 1 (Compound 114) is a D3R/MOR antagonist (K _i : 46.5 nM and 691 nM respectively). D3R/MOR antagonist 1 has the potential to produce analgesic effects through MOR partial agonism, reduce opioid-misuse liability via D3R antagonism ^[1] .
IC ₅₀ & Target	46.5 nM and 691 nM (D3R/MOR) ^[1]

REFERENCES

[1]. Bonifazi A, et al. Pharmacological and Physicochemical Properties Optimization for Dual-Target Dopamine D3 (D3R) and µ-Opioid (MOR) Receptor Ligands as Potentially Safer Analgesics. J Med Chem. 2023 Aug 10;66(15):10304-10341.

Caution: Product has not been fully validated for medical applications. For research use only.

Fax: 609-228-5909 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA CI

CI

Product Data Sheet



Tel: 609-228-6898

E-mail: tech@MedChemExpress.com